A Novel Apilic Antivenom to Treat Massive, Africanized Honeybee Attacks: A Preclinical Study from the Lethality to Some Biochemical and Pharmacological Activities Neutralization.
Article in Toxins, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 11 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 3 institutions in 1 country.
Jhonatha Mota Teixeira-CruzGraduate Program in Pharmacology and Medicinal Chemistry, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0002-3167-0723
Marcelo Abrahão StrauchGraduate Program in Pharmacology and Medicinal Chemistry, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.
Marcos Monteiro-MachadoGraduate Program in Pharmacology and Medicinal Chemistry, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0002-1657-1356
Matheus Silva Tavares-HenriquesGraduate Program in Pharmacology and Medicinal Chemistry, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0003-0197-9778
João Alfredo de MoraesGraduate Program in Pharmacology and Medicinal Chemistry, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0002-8563-6432
Luís Eduardo Ribeiro da CunhaScientific Board, Vital Brazil Institute (IVB), Niterói, Rio de Janeiro 24230-410, Brazil.
Rui Seabra FerreiraCenter for the Study of Venoms and Venomous Animals (CEVAP), São Paulo State University (UNESP), Botucatu, São Paulo 18610-307, Brazil.ORCID 0000-0001-6952-0512
Benedito BarravieraCenter for the Study of Venoms and Venomous Animals (CEVAP), São Paulo State University (UNESP), Botucatu, São Paulo 18610-307, Brazil.
Luis Eduardo M QuintasGraduate Program in Pharmacology and Medicinal Chemistry, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.ORCID 0000-0002-0767-1240
Paulo A MeloGraduate Program in Pharmacology and Medicinal Chemistry, Institute of Biomedical Sciences, Federal University of Rio de Janeiro, Rio de Janeiro 21941-902, Brazil.
Universidade Federal do Rio de Janeiro · BRUniversidade Estadual Paulista (Unesp) · BRInstituto Vital Brazil (Brazil) · BR
Funding
QUANTITATIVE STUDIES OF THE CENTRAL VISUAL SYSTEMR01EY002017 · NEI · NEW YORK UNIVERSITY · PI MOVSHON, J ANTHONY · 1986 to 2008
$1.7M
Conselho Nacional de Desenvolvimento Científico e Tecnológico 401170/2013-6Conselho Nacional de Desenvolvimento Científico e Tecnológico 409436/2016-0Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 23038.006285/2011-21Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro E_02/2017Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro e-26/200.006/2018
6 · The paper itself
Abstract
Massive, Africanized honeybee attacks have increased in Brazil over the years. Humans and animals present local and systemic effects after envenomation, and there is no specific treatment for this potentially lethal event. This study evaluated the ability of a new Apilic antivenom, which is composed of F(ab')2 fraction of specific immunoglobulins in heterologous and hyperimmune equine serum, to neutralize
Indexed as
AnimalsAntibodiesAntiveninsBeesBee VenomsBites and StingsBrazilCell LineCell SurvivalDose-Response Relationship, DrugDrug Evaluation, PreclinicalFemaleHemolysisHorsesHyaluronoglucosaminidaseImmunoglobulin Fab FragmentsAntibodiesAntiveninsBee VenomsHyaluronoglucosaminidaseImmunoglobulin Fab FragmentsMelittenPhospholipasesApilic antivenomApis melliferaenvenomationhoneybee venommelittinpreclinical study
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Novel Apilic Antivenom to Treat Massive, Africanized Honeybee Attacks: A Preclinical Study from the Lethality to Some Biochemical and Pharmacological Activities Neutralization. · full record | OpenQuestion